Ochi Shinichiro, Inoue Saori, Yoshino Yuta, Shimizu Hideaki, Iga Jun-Ichi, Ueno Shu-Ichi
Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Toon, Japan.
Clin Psychopharmacol Neurosci. 2019 Nov 20;17(4):559-563. doi: 10.9758/cpn.2019.17.4.559.
Schizophrenic patients resistant to antipsychotics are diagnosed as having treatment-refractory schizophrenia, and they are treated with clozapine. However, clozapine is sometimes combined with electroconvulsive therapy (ECT) if clozapine monotherapy fails. In this report, a severe treatment-refractory schizophrenic patient who did not respond to clozapine even with ECT, but who recovered with asenapine monotherapy, is presented. Asenapine, considered a serotonin spectrum dopamine modulator, is a new atypical antipsychotic with unique pharmacological features that is used not only for schizophrenia, but also for bipolar disorder. The unique features of asenapine may be effective for some treatment-refractory schizophrenic patients.
对抗精神病药物耐药的精神分裂症患者被诊断为难治性精神分裂症，并用氯氮平进行治疗。然而，如果氯氮平单药治疗失败，氯氮平有时会与电休克疗法（ECT）联合使用。在本报告中，介绍了一名严重难治性精神分裂症患者，即使接受ECT治疗，对氯氮平也无反应，但接受阿立哌唑单药治疗后康复。阿立哌唑被认为是一种5-羟色胺能多巴胺调节剂，是一种具有独特药理特性的新型非典型抗精神病药物，不仅用于治疗精神分裂症，还用于治疗双相情感障碍。阿立哌唑的独特特性可能对一些难治性精神分裂症患者有效。
